Liver function and safety of TQ05105 tablet
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests how a tablet called TQ05105 is processed in people with different levels of liver function. It helps doctors understand the right dose for patients with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have either normal liver function or mild to moderate liver impairment (Child-Pugh Grade A or B).
- You cannot have severe liver failure, liver cancer, or a history of liver transplant.
- You must not have used certain medications or supplements that affect liver enzymes within the past 4 weeks.
- You must not smoke more than 5 cigarettes a day or have a history of drug abuse.
- You must agree to use effective birth control and not donate sperm or eggs for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQ05105 to see if it can help people with a blood-marrow disease called myelofibrosis. The study focuses on patients whose condition is moderate to severe and measures how well the drug works and how safe it is.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study checks how a new tablet moves through the body and if it is safe for people with mild or moderate liver problems compared to people with healthy livers. It might help doctors understand how to dose the drug for people like you.
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
This trial is testing an investigational drug called TQ05105 for people with moderate to severe chronic graft-versus-host disease (GVHD) after a stem cell transplant. It may offer a new treatment option if current therapies are not working well enough.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.